BioMark Diagnostics, Inc. · CSE:BUX

BioMark Diagnostics — Investor Presentation (April 2023)

42 slides from BioMark Diagnostics's investor presentation, April 2023

  1. Slide 1: A Next Generation Company Powered by Metabolomics and Artificial Intelligence

    Slide 1: A Next Generation Company Powered by Metabolomics and Artificial Intelligence

    A NEXT GENERATION COMPANY POWERED BY METABOLOMICS AND ARTIFICIAL INTELLIGENCE

  2. Slide 2: Investment Highlights

    Slide 2: Investment Highlights

    INVESTMENT HIGHLIGHTS INTEGRATED TECHNOLOGY PLATFORM: UNIQUE INTEGRATION OF METABOLOMICS AND MACHINE LEARNING USING VERSATILE HIGH THROUGHPUT/SENSITIVE AND SCALABLE INSTRUMENTS DESIGNED TO DELIVER SUPERIOR CLINICAL OUTCOME BROAD APPLICATION: EARLY DETECTION MEASURING RESPONSE TO TREATMENT MONITOR FO

  3. Slide 3: Our Mission – seek positive change in cancer care

    Slide 3: Our Mission – seek positive change in cancer care

    Our Mission – seek positive Bio-Mark change in cancer care • A developer of a metabolomics liquid To improve cancer care biopsy-based platform leveraging management by providing robust machine learning with advanced near-to- diagnostic tools to guide market diagnostic technologies. treatment for har

  4. Slide 4: BioMark's Tools Designed To Improve Cancer Care Management

    Slide 4: BioMark's Tools Designed To Improve Cancer Care Management

    BioMark’s Tools Designed To Improve Cancer Care Management • Accelerate early detection – Stage shifting can improve survival rates through early effective intervention • Dynamically monitor response to treatment – select treatments that are more effective faster • Monitor for recurrence – most of t

  5. Slide 5: BioMark Uses Metabolomics

    Slide 5: BioMark Uses Metabolomics

    BIOMARK USES METABOLOMICS me·​tab·​o·​lo·​mics | \ mə-ˈta-bə-ˌlō-miks : a form of clinical chemistry that uses advanced analytical techniques to measure the complete collection of “small molecules” found in a given biological sample . It offers rapid, inexpensive, comprehensive, quantitative charact

  6. Slide 6: Cancer Is a Metabolic Disease

    Slide 6: Cancer Is a Metabolic Disease

    CANCER IS A METABOLIC DISEASE 6 Source: Hallmarks of Cancer - Hanahan D, Wienberg RA (2011) Cell, 144:646-674.

  7. Slide 7: The Advantages of Metabolomics

    Slide 7: The Advantages of Metabolomics

    THE ADVANTAGES OF METABOLOMICS Metabolic biochemical reaction is an ancient and conservative process, similar across different species, that is strictly regulated by the organism. Therefore, the metabolic difference between individuals is much smaller than that of genes and proteins. Metabolomics is

  8. Slide 8: Technology Platform & Product Pipeline

    Slide 8: Technology Platform & Product Pipeline

    TECHNOLOGY PLATFORM & PRODUCT PIPELINE Planning Development Validation Regulatory Approval Market Assay customization- Prospective clinical trial underway Early Lung Cancer Metabolic Panel Assay ( 9 biomarkers) involving 4000 patients. Assay will be to a Lab Developed Test (LDT) for early lung cance

  9. Slide 9: Clinical Studies and Validation Projects in Progress

    Slide 9: Clinical Studies and Validation Projects in Progress

    CLINICAL STUDIES AND VALIDATION PROJECTS IN PROGRESS Metabolomic Fingerprint Assay Development: Early Lung Cancer KOL in Canada, US and Europe • Completed >800 in an independent retrospective sample studies following 260 trial at IUCP Quebec. Expanded the sample size to include more subtypes, other

  10. Slide 10: Clinical Studies and Validation Projects in Progress

    Slide 10: Clinical Studies and Validation Projects in Progress

    CLINICAL STUDIES AND VALIDATION PROJECTS IN PROGRESS Response to Treatment Studies using SSAT1 Assay: Advanced Stage Lung Cancer (radio and chemo therapies) • Proof of concept studies. Expanded study scope and site to include immunotherapy. Sites – IUCP Quebec and CancerCare Manitoba. IUCP Quebec fu

  11. Slide 11: Patent Family in Use in Different Jurisdictions

    Slide 11: Patent Family in Use in Different Jurisdictions

    PATENT FAMILY IN USE IN DIFFERENT JURISDICTIONS SSAT1 Assay Lung Cancer Metabolic GBM Therapeutic Response to treatment Panel Target in lung and brain cancers METHOD OF DETECTING LUNG GLIOBLASTOMA TUMOR A METHOD FOR ASSAYING THE CANCER GROWTH INHIBITON BY SAT1 ACTIVITY OF KNOCKDOWN SPERMIDINE/SPERMI

  12. Slide 12: Lung Cancer Metabolic Fingerprint Assay

    Slide 12: Lung Cancer Metabolic Fingerprint Assay

    Lung Cancer Metabolic Fingerprint Assay 12

  13. Slide 13: Lung Cancer – The Big Picture

    Slide 13: Lung Cancer – The Big Picture

    LUNG CANCER – THE BIG PICTURE Lung cancer - most common cancer Most common in the world for several decades and accounts for 1 in 5 of all cancer deaths. Worldwide, three people die from lung Deadly cancer every minute High false positive rates Currently, 96 % of all nodules discovered via Low-Dose

  14. Slide 14: Early Detection Is Critical to Saving Lives

    Slide 14: Early Detection Is Critical to Saving Lives

    EARLY DETECTION IS CRITICAL TO SAVING LIVES 14

  15. Slide 15: Early Lung Cancer Metabolic Assay Designed for Easy Deployment

    Slide 15: Early Lung Cancer Metabolic Assay Designed for Easy Deployment

    EARLY LUNG CANCER METABOLIC ASSAY DESIGNED FOR EASY DEPLOYMENT • Use quantitative mass spectrometry (MS) methods with standard instruments common in diagnostic clinical laboratories across Canada and USA. • Lung cancer metabolites are easily measured: <20 µL of blood required • Time to perform the t

  16. Slide 16: Lung Cancer: Problem and Our Solution

    Slide 16: Lung Cancer: Problem and Our Solution

    LUNG CANCER Lung cancer is the most common cancer in the world for several decades and accounts for 1 in 5 of all cancer deaths PROBLEM OUR SOLUTION X DETECTED LATE ONLY 16 % OF LUNG CANCER CASES ARE √ STAGE SHIFT FOCUS ON EARLY DETECTION – STAGES I AND DIAGNOSED AT AN EARLY STAGE. AS A RESULT, II W

  17. Slide 17: Retrospective Study Discovered Metabolomics Biomarkers

    Slide 17: Retrospective Study Discovered Metabolomics Biomarkers

    Retrospective study discovered metabolomics biomarkers for the early detection of lung cancer Data Summary Total Subjects: 257 Healthy : 60 Lung Cancer: 197 (emphasis on Stages 1 and 2) Metabolomics Analysis: Human plasma samples* were analyzed using targeted panel of several putative lung cancer bi

  18. Slide 18: Lung Cancer Metabolic Panel – Strong Performance for Early-Stage Detection

    Slide 18: Lung Cancer Metabolic Panel – Strong Performance for Early-Stage Detection

    LUNG CANCER METABOLIC PANEL-STRONG PERFORMANCE FOR EARLY- STAGE DETECTION P E R F O R M AN C E O F L O G I S T I C R E G R E S S I O N P E R F O R M AN C E O F L O G I S T I C R E G R E S S I O N M O D E L A MODEL B AUC SENSITIVITY SPECIFICITY AUC SENSITIVITY SPECIFICITY TRAINING/ 0.974 (0.965 ~ 0.9

  19. Slide 19: Large-Scale Retrospective Validation Study Confirmed Biomarkers

    Slide 19: Large-Scale Retrospective Validation Study Confirmed Biomarkers

    Large-scale retrospective validation study confirmed biomarkers for the early detection of lung cancer Stage I & II NSCLC 9-Biomarker Panel Stage III & IV NSCLC 9-Biomarker Panel • The metabolites discovered were robust and continue to demonstrate reproducibility for early-stage NSCLC cancer detecti

  20. Slide 20: Strong Performance for Early-Stage Lung Detection Assay

    Slide 20: Strong Performance for Early-Stage Lung Detection Assay

    STRONG PERFORMANCE FOR EARLY-STAGE LUNG DETECTION ASSAY Stage I & II NSCLC 9-Biomarker Panel • The markers discovered can differentiate lung cancer from lung diseases quite reliably. • This validation of previously identified biomarkers in a larger cohort illustrate how metabolomics fingerprinting h

  21. Slide 21: Lung Cancer Screening Demonstration Project

    Slide 21: Lung Cancer Screening Demonstration Project

    LUNG CANCER SCREENING DEMONSTRATION PROJECT DISCOVERY COHORT VALIDATION COHORT Screening project T1 year T2 year T3 year Patient selection (PanCan risk model); n=3000 Genetic profile Clinical follow-up Polygenic score No lesion IUCPQ Biobank EGFR Status Low risk lesion 4,000 lung lesion patients ✓ C

  22. Slide 22: Commercialization Roadmap of Lung Assay in Quebec

    Slide 22: Commercialization Roadmap of Lung Assay in Quebec

    COMMERCIALIZATION ROADMAP OF LUNG ASSAY IN QUEBEC Lung Cancer Metabolic Panel Development Timeline Revenue Commence Lung Stage I/II Cancer Discovery Screening Present data Study Open R&D Internal Validation CQDM to regulatory Publication Facilities in Qc Assay V&V (4000 samples) agencies 2020 2021 2

  23. Slide 23: Fully Integrated System

    Slide 23: Fully Integrated System

    FULLY INTEGRATED SYSTEM Robotics and Automated Sample handling Faster and Cleaner Extraction High throughput: up to 1500 tests per day Sample extraction to analysis < 45 min Highly sensitive – low limit of detection levels Multiple analysis on same sample Sample required < 100uL 23

  24. Slide 24: Activities to Introduce and Grow Early Lung Cancer LDT Assay

    Slide 24: Activities to Introduce and Grow Early Lung Cancer LDT Assay

    ACTIVITIES TO INTRODUCE AND GROW EARLY LUNG CANCER LAB DEVELOPED TEST (LDT) ASSAY • Achievement of ISO -15189 accredited lab services certification in Quebec to accommodate client sample analysis • Establish beachhead in Quebec at IUCPQ and expand screening services across Canada, US, S. America and

  25. Slide 25: Regulatory Pathway

    Slide 25: Regulatory Pathway

    REGULATORY PATHWAY Proposed Assay – Lab Developed Test (LTD) is a type of in vitro diagnostic test that is designed, manufactured and used within a single laboratory. The labs need to have ISO 15-189 (Canada) and CLIA (US) certification for high complexity test Rationale: • Easier route to introduce

  26. Slide 26: Reimbursement

    Slide 26: Reimbursement

    REIMBURSEMENT Drivers • Cost vs other molecular and imaging modalities • Existing CPT code* and AMA approval – MDM (Medical Decision Making) for high complexity test aided by algorithms • Data – lower false +ve rates – lower waste – Good Positive Predictive Value - PPV • CLIA certification and quali

  27. Slide 27: Catalysts in Q1-Q3 2023

    Slide 27: Catalysts in Q1-Q3 2023

    CATALYSTS IN Q1-Q3 2023 Completed 1200 retrospective early lung cancer analysis and data readout –Presented interim data at ESMO 2022. Abstract published in Annals of Oncology Journal. Recruited over 2000 patients for the multimodal early lung cancer 4000 patient trial involving AZ; Pfizer; IUCPQ; O

  28. Slide 28: Business Model for Early Lung Cancer Detection

    Slide 28: Business Model for Early Lung Cancer Detection

    Business Model for Early Lung Cancer Detection ACTIVITY MARKET REVENUE SOURCE TIMING PROVIDE TEST SERVICE FROM QUEBEC – CANADA; CERTIFIED CLINICAL LAB NORTHEAST USA  DIRECT SALES OF LDT O P E R AT I O N I N Q U E B E C . U S E 2023/24 LUNG CANCER TEST C A PA C I T Y T O S E R V I C E SCREENING N.EA

  29. Slide 29: Potential Revenue

    Slide 29: Potential Revenue

    Potential Revenue Total North American Market Valued at $4.4B AT RISK POPULATION 23/24 24/25 25/26 26/27 27/28 QUEBEC - 380K 1% 5% 10% 15% 20% ONTARIO- 600K 2% 5% 10% 12% INFLECTION ALBERTA- 200K 2% 5% 10% 12% POINTS M&A OTHER- 200K 5% 10% 10% INFLECTION POINTS US- 16M 0.0% 0.5% 2% 5% 7% NASDAQ Addr

  30. Slide 30: Use of Funds to Set Stage for Revenue Generation

    Slide 30: Use of Funds to Set Stage for Revenue Generation

    USE OF FUNDS TO SET STAGE FOR REVENUE GENERATION P r i va te P l a c e m e nt up to $ 5 M CAD i n c om m on s ha r e s + w a r r ants High-complexity General Human resource Molecular Lab Operating costs and Operation and and infrastructure Certification Market IR US and Regulatory, R&D for other Int

  31. Slide 31: Collaborators

    Slide 31: Collaborators

    COLLABORATORS )RsSRa AstraZeneca? KE ERLae See Phytronim } NEUROENDOCRINE TUMOUR SOCIETY institute of Canadi esters MCF Ghaamy Fun De cancer Y Uh CIHR RSC lee 1) eh Ww Z| Ul [iicmmnce LE CAMP Acubateur - Accélérateur istvur @ < e DE CARD = a ETDEPN. Sj a De QUES! x £ The etbolomies novation UNIVERSI

  32. Slide 32: Strong Tailwinds

    Slide 32: Strong Tailwinds

    STRONG TAILWINDS • Current lung cancer screening rates in US is estimated at 5% • Limited access to LDCT especially in rural communities • Active VA screening programs seeking better screening technology for at risk veterans across the country. Program under being funded by NCI • Cancer Moonshot has

  33. Slide 33: Ideal Characteristic Market – Hospitals and Medical Institutions

    Slide 33: Ideal Characteristic Market – Hospitals and Medical Institutions

    IDEAL CHARACTERISTIC MARKET –HOSPITALS AND MEDICAL INSTITUTIONS • Rural Communities* • Inner-City Communities • Low-to-Moderate Income Areas • Underserved Populations (Minority, Female, Veteran) • Medically Underserved Areas (MUAs) • Health Professional Shortage Areas (HPSAs) *Rural populations tend

  34. Slide 34: What Drives the Management Culture?

    Slide 34: What Drives the Management Culture?

    WHAT DRIVES THE MANAGEMENT CULTURE ? ➢ Collaborate For Impact – Seek and value different perspectives and experiences to shape better outcomes. ➢ Stay Curious – Seek to understand and continuously innovate for positive impact. ➢ Perform and deliver 34

  35. Slide 35: Management Team

    Slide 35: Management Team

    MANAGEMENT TEAM Rashid A. Bux - Founder & CEO Rashid Ahmed - Founder and CEO of BioMark Diagnostics Inc, started his journey into the medical sector as a science student at Nairobi University. He holds a Master of Business Administration from the University of Western Ontario and a Bachelor of Scien

  36. Slide 36: Management Team

    Slide 36: Management Team

    MANAGEMENT TEAM Guoyu Huang – CFO Guoyu (Gina) Huang, been a management team member of BioMark Diagnostics Inc. since 2013 where she has been instrumental in establishing a robust and transparent corporate structure. Her exceptional ability and diverse experience allow her to examine and understand

  37. Slide 37: Management Team

    Slide 37: Management Team

    MANAGEMENT TEAM Dr. Jean-Francois Haince - CSO and GM Dr. Haince, holds a PhD in Cellular and Molecular Biology from the Faculty of Medicine at Université Laval. He cumulates over 15 years of experience in cancer research and has authored over 20 peer-reviewed scientific publications. Dr. Haince als

  38. Slide 38: Strategic and Scientific Advisors

    Slide 38: Strategic and Scientific Advisors

    Strategic and Scientific Advisors Mr. Alfred R. Berkeley – Strategic and financial advisor Dr. David Wishart – Professor, Depts. of Computer Science and Biological Sciences, University of Alberta Dr. Philippe Joubert – M.D. Anatomopathologist at the Quebec Heart and Lung Institute (IUCPQ-UL) Dr. Chr

  39. Slide 39: BioMark Corporate Structure

    Slide 39: BioMark Corporate Structure

    BIOMARK CORPORATE STRUCTURE MIX OF PUBLIC AND PRIVATE ENTITIES IDEAL FOR ALL TYPE OF INVESTORS 39

  40. Slide 40: BioMark Cap Table Summary

    Slide 40: BioMark Cap Table Summary

    BIOMARK CAP TABLE SUMMARY • Trading Symbols: CSE: BUX / OTCMKTS: BMKDF / FSE: 20B • Common Shares Issued and Outstanding: 83,036,229 • Warrants (@ $0.45): 6,177,579 • Options (@ $0.15 - $0.30): 4,135,000 • Insiders ownership: 68% • Capital Raised (to-date): CAD $ 19 M 40

  41. Slide 41: Key Takeaways

    Slide 41: Key Takeaways

    KEY TAKEAWAYS • Strong diagnostic platform for hard to detect and treat cancer • Lung cancer assay near commercialization. • Initiating business development and partnering activities as global lung cancer cases expanding • Significant near-term data readout on early lung cancer • Large addressable g

  42. Slide 42: Contact Details

    Slide 42: Contact Details

    Contact Details Rashid Bux Founder and CEO rahmed@biomarkdiagnostics.com Mobile: 1- 604-836-6950 www.biomarkdiagnostics.com A NEXT GENERATION COMPANY POWERED BY METABOLOMICS AND 42 ARTIFICIAL INTELLIGENCE

Source: Internet Archive copy of biomarkdiagnostics.com

More decks from BioMark Diagnostics, Inc.

All 7 BioMark Diagnostics decks